Skip to content
Clinical Trials – home

Aarhus University Hospital

Verified siteinfo

Denmark Palle Juul-Jensen Blvd 99, 8200 Aarhus, Denmark

  • 110 trials recruiting
  • Plasma cell myeloma · Pulmonary arterial hypertension · Chronic kidney disease
  • Adults and children

About Specializations

Aarhus University Hospital in Aarhus, Denmark specialises in clinical trials of conditions such as Plasma cell myeloma, Pulmonary arterial hypertension, Chronic kidney disease, Dermatitis atopic, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Nervous System Diseases

At Aarhus University Hospital, clinical research in these therapeutic areas focuses on the link between cardiovascular health and neurological injury, with a strong emphasis on conditions that affect blood flow to the brain.

  • Ischemic stroke is the main disease under study, reflecting interest in improving outcomes after disrupted cerebral circulation.
  • Trials are exploring whether new treatments can support recovery and reduce complications in the acute phase of stroke.
  • Research also aims to better understand how therapies may protect both the brain and the wider vascular system.

This work is centered on testing new treatment approaches and evaluating their safety and effectiveness for people affected by acute stroke.

Neurology Research in Acute Stroke Care

The Department of Neurology at this site is conducting clinical trials that concentrate on urgent treatment needs in ischemic stroke, with the goal of improving care during the earliest and most critical stage of illness.

  • Research is directed at identifying therapies that may improve neurological recovery after stroke.
  • Studies are also assessing whether a new intervention can be safely used soon after the event.
  • The overall focus is on advancing treatment options for patients with acute brain ischemia.

One example is the ASSET Trial, which is examining whether semaglutide may be helpful in the acute phase after stroke.

Stroke Treatment Innovation

Clinical trial activity at Aarhus University Hospital includes research into new ways to manage acute ischemic stroke, combining expertise in neurology and vascular disease.

  • The main disease focus is ischemic stroke, a major cause of disability and long-term neurological impairment.
  • Trials are designed to test whether emerging therapies can improve patient outcomes after stroke.
  • There is also interest in understanding the broader role of metabolic and cardiovascular treatments in brain recovery.

These studies are intended to support better treatment decisions and expand the options available for patients in the acute setting.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Palle Juul-Jensen Blvd 998200 AarhusDenmark
Recruiting now
110 trials
Conditions studied
242
Partner status
Verified site

More sites in AarhusDenmark

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

310 clinical trials

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Ferring Pharmaceuticals A/S

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Dermatomyositis+1

Recruiting

Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

A Study of ANX005 for Patients Recently Diagnosed with Guillain-Barré Syndrome to Evaluate How the Drug Works in the Body and Its Safety

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Humanised IgG4 monoclonal antibody against C1Q
  • Sponsor:Annexon Inc.

A study evaluating the effect of methylprednisolone compared to sodium chloride in patients with a heart attack

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Region Hovedstaden

Increasing the dose of glimepiride for patients with HNF1A-MODY or HNF4A-MODY diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glimepiride
  • Sponsor:Steno Diabetes Center Copenhagen

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.